Quest Diagnostics Incorporated Research Note: Growth Meets a Margin and Mix Test
Quest Diagnostics enters its October 22 update with strong growth, a complex volume mix and questions about revenue per requisition and margins.
Quest Diagnostics enters its October 22 update with strong growth, a complex volume mix and questions about revenue per requisition and margins.
SS&C Technologies enters its October 22 update with stronger organic growth and cash flow, while leverage and recent price strength raise the proof bar.
MaxLinear’s Q2 growth shifted toward infrastructure, while the October 22 update will test margins, cash generation, inventory, and concentration.
Medpace’s strong second-quarter awards and cash profile face an October 21 test of backlog conversion, sponsor demand and margin durability.
Crown Castle tower economics face an October 21 test of revenue durability, organic leasing, tenant concentration and post-sale balance-sheet progress.
Wabtec’s broad rail growth and margin gains face an October 21 test of backlog conversion, cash generation, acquisition mix and debt discipline.
Danaher’s improving core growth and cash generation face an October 21 test shaped by bioprocessing conversion, acquisition leverage, and valuation.
Hancock Whitney approaches its next update with improving credit, solid capital, and a fresh test of One Florida integration and deposit resilience.
General Motors reaches its October 20 update with stronger adjusted margins and cash generation, while softer U.S. sales sharpen the test of durability.
W. R. Berkley approaches its October 19 update with profitable underwriting, rising investment income and a focused test of reserve quality.